Program
Atorvastatin
Also written as “atorvastatin”, “Atorvastatin 20 mg” and “Comparator: atorvastatin”.
Its studies are mostly in Hypercholesterolemia · Dyslipidemias · Hyperlipidemias · Diabetes Mellitus, Type 2 · Cardiovascular Diseases, led by 22 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Viatris | 290 open or running | phase 4since Aug 30, 2005 | Aug 25, 2005 | none ahead |
| Organon | 200 open or running | phase 4since Apr 1, 2008 | Sep 23, 2004 | none ahead |
| Pfizer | 160 open or running | phase 4since Sep 6, 2005 | Aug 22, 2005 | none ahead |
| Chong Kun Dang Pharmaceutical | 60 open or running | phase 4since Nov 16, 2009 | Nov 16, 2009 | none ahead |
| Dr. Reddy's Laboratories | 60 open or running | phase 1since Jul 18, 2012 | Jul 18, 2012 | none ahead |
| GlaxoSmithKline | 60 open or running | phase 3since Dec 15, 2011 | Dec 11, 2006 | none ahead |
| Astellas Pharma | 30 open or running | phase 4since Dec 5, 2006 | Dec 5, 2006 | none ahead |
| Daiichi Sankyo | 30 open or running | phase 4since Sep 16, 2008 | Sep 16, 2008 | none ahead |
| midas-pharma-gmbh | 20 open or running | phase 1since Jan 23, 2020 | Jan 23, 2020 | none ahead |
| Sun Pharmaceutical Industries | 20 open or running | phase 1since Dec 20, 2011 | Dec 20, 2011 | none ahead |
| Azidus Brasil | 10 open or running | phase 1since Sep 21, 2012 | Sep 21, 2012 | none ahead |
| clinical-research-management-inc | 10 open or running | phase 2since Mar 1, 2015 | Mar 1, 2015 | none ahead |
| Cumberland Pharmaceuticals | 10 open or running | phase 2since Jul 19, 2018 | Jul 19, 2018 | none ahead |
| Daewon Pharmaceutical | 10 open or running | phase 3since Jul 24, 2023 | Jul 24, 2023 | none ahead |
| Daewoong Pharmaceutical | 10 open or running | phase 3since Oct 26, 2016 | Oct 26, 2016 | none ahead |
| dr-md-alimur-reza | 10 open or running | phase 4since Jan 17, 2025 | Jan 17, 2025 | none ahead |
| Huons Global | 11 open or running | phase 1since Aug 5, 2026 | Aug 5, 2026 | Apr 2027phase 1 · NCT07784608 |
| Intarcia Therapeutics | 10 open or running | phase 1since Dec 21, 2015 | Dec 21, 2015 | none ahead |
| Jeil Pharmaceutical | 10 open or running | phase 1since Mar 5, 2018 | Mar 5, 2018 | none ahead |
| Laboratorios Silanes S.A. de C.V. | 10 open or running | phase 3since Apr 29, 2021 | Apr 29, 2021 | none ahead |
| Profil Institut für Stoffwechselforschung | 10 open or running | phase 1since Sep 9, 2009 | Sep 9, 2009 | none ahead |
| samil-pharmaceutical-co-ltd | 10 open or running | phase 1since Oct 13, 2015 | Oct 13, 2015 | none ahead |
Also a collaborator on its studies: parexel, pharma-medica-research-inc, Merck, Regeneron Pharmaceuticals, mds-pharma-services, celerion, Sanofi and basilea-pharmaceutica-international-ltd.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 43 studies since Mar 26, 2008.
- Oct 26, 2016Daewoong Pharmaceutical's first study: phase 3 study in Diabetes Mellitus, Type 2New to Daewoong PharmaceuticalDaewoong Pharmaceutical · NCT02947620 · 185 enrolled · Korea, Republic of
- Nov 27, 2016Phase 2 study in DyslipidemiasChong Kun Dang Pharmaceutical · NCT02977065 · 62 enrolled · Australia
- Jan 23, 2017Phase 1 study in Non-alcoholic Fatty Liver DiseasePfizer · NCT03031119 · 62 enrolled · Belgium
- Mar 5, 2018Jeil Pharmaceutical's first study: phase 1 study in Hypertension With HyperlipidemiaNew to Jeil PharmaceuticalJeil Pharmaceutical · NCT03461081 · 32 enrolled · Korea, Republic of
- Jul 19, 2018Cumberland Pharmaceuticals's first study: phase 2 study in HypercholesterolemiaNew to Cumberland PharmaceuticalsCumberland Pharmaceuticals · NCT03611010 · 40 enrolled · United States
- Mar 6, 20193 phase 3 studiesOrganon · NCT03884452, NCT03867318, NCT03867110
- Jan 23, 2020midas-pharma-gmbh's first study: phase 1 study in Healthy VolunteersNew to midas-pharma-gmbhmidas-pharma-gmbh · NCT04245046 · 18 enrolled · Jordan
- Feb 7, 2020Phase 1 study in Healthy Volunteersmidas-pharma-gmbh · NCT04262765 · 18 enrolled · Jordan
- Apr 29, 2021Laboratorios Silanes S.A. de C.V.'s first study: phase 3 study in DyslipidemiasNew to Laboratorios Silanes S.A. de C.V.Laboratorios Silanes S.A. de C.V. · NCT04882293 · 78 enrolled · Mexico
- Oct 13, 2021Phase 1 study in Healthy AdultsPfizer · NCT05093205 · 35 enrolled · United States
- Jul 24, 2023Daewon Pharmaceutical's first study: phase 3 study in HypercholesterolemiaNew to Daewon PharmaceuticalDaewon Pharmaceutical · NCT05970679 · 252 enrolled · Korea, Republic of
- Jan 17, 2025dr-md-alimur-reza's first study: phase 4 study in HyperlipidemiasNew to dr-md-alimur-rezadr-md-alimur-reza · NCT06789432 · Bangladesh
- Nov 14, 20252 phase 1 studies in Healthy SubjectsDaiichi Sankyo · NCT07235189, NCT07268625
- Aug 5, 2026Huons Global's first study: phase 1 study in Drug-drug InteractionsNew to Huons GlobalHuons Global · NCT07784608 · 28 planned · South Korea
Ahead
- Apr 2027Primary completion: phase 1 study in Drug-drug InteractionsHuons Global · NCT07784608
TargetBeta
“HMG-CoA reductase inhibitor”ChEMBL 37, by rule
Other programs on HMGCR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| rosuvastatinrule | AstraZeneca | phase 4 | 184 |
| Simvastatinrule | Organon | phase 4 | 100 |
| pitavastatinrule | Kowa | phase 4 | 36 |
Studies
The newest 60 of 105 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07784608Drug-drug Interactions · South Korea | 1 | Not yet recruiting | Huons Global | Apr 2027 | 28 |
| NCT07268625Healthy Subjects · Portugal | 1 | Completed | Daiichi Sankyo | Feb 24, 2026 | 58 |
| NCT07235189Healthy Subjects · Portugal | 1 | Completed | Daiichi Sankyo | Jan 28, 2026 | 58 |
| NCT06789432Hyperlipidemias · Bangladesh | 4 | Withdrawn | dr-md-alimur-reza | Oct 2025 | 0 |
| NCT05970679Hypercholesterolemia · Korea, Republic of | 3 | Completed | Daewon Pharmaceutical | Apr 13, 2023 | 252 |
| NCT05093205Healthy Adults · United States | 1 | Completed | Pfizer | Jul 6, 2022 | 35 |
| NCT04882293Dyslipidemias · Mexico | 3 | UNKNOWN | Laboratorios Silanes S.A. de C.V. | May 2022 | 78 |
| NCT04262765Healthy Volunteers · Jordan | 1 | Completed | midas-pharma-gmbh | Mar 26, 2019 | 18 |
| NCT04245046Healthy Volunteers · Jordan | 1 | Completed | midas-pharma-gmbh | Feb 18, 2019 | 18 |
| NCT03884452Hyperlipoproteinemia Type II | 3 | Completed | Organon | May 24, 2001 | 50 |
| NCT03867318Hypercholesterolemia | 3 | Completed | Organon | Nov 16, 2001 | 621 |
| NCT03867110Hypercholesterolemia | 3 | Completed | Organon | Jul 27, 2001 | 628 |
| NCT03611010Hypercholesterolemia · United States | 2 | Completed | Cumberland Pharmaceuticals | Feb 17, 2020 | 40 |
| NCT03461081Hypertension With Hyperlipidemia · Korea, Republic of | 1 | Completed | Jeil Pharmaceutical | Jul 12, 2017 | 32 |
| NCT03031119Non-alcoholic Fatty Liver Disease · Belgium | 1 | Completed | Pfizer | Jul 2017 | 62 |
| NCT02977065Dyslipidemias · Australia | 2 | Completed | Chong Kun Dang Pharmaceutical | Dec 30, 2017 | 62 |
| NCT02947620Diabetes Mellitus, Type 2 · Korea, Republic of | 3 | Completed | Daewoong Pharmaceutical | Feb 27, 2017 | 185 |
| NCT02641899Healthy · United States | 1 | Completed | Intarcia Therapeutics | Mar 2016 | 33 |
| NCT02579356Essential Hypertension · Korea, Republic of | 1 | Completed | samil-pharmaceutical-co-ltd | Aug 2014 | 48 |
| NCT02550288Hypercholesterolemia | 3 | Completed | Organon | May 30, 2016 | 309 |
| NCT02460159Hypercholesterolemia | 3 | Completed | Organon | Dec 22, 2016 | 135 |
| NCT02422030Healthy · Korea, Republic of | 1 | Completed | Chong Kun Dang Pharmaceutical | Mar 22, 2015 | 30 |
| NCT02380625Hemorrhagic Fever, Ebola | 2 | UNKNOWN | clinical-research-management-inc | Jan 2016 | 150 |
| NCT02295046Healthy · Germany | 1 | Completed | Dr. Reddy's Laboratories | Oct 2011 | 80 |
| NCT02292069Healthy · India | 1 | Completed | Dr. Reddy's Laboratories | Sep 2011 | 90 |
| NCT02288338Healthy · Korea, Republic of | 1 | Completed | Chong Kun Dang Pharmaceutical | Feb 2015 | 36 |
| NCT02066207Dyslipidemias · Korea, Republic of | 1 | Completed | Chong Kun Dang Pharmaceutical | Apr 7, 2014 | 30 |
| NCT01964326Hypercholesterolemia · United States | 3 | Completed | Viatris | Dec 2014 | 1,311 |
| NCT01842256Essential Hypertension · Korea, Republic of | 1 | Completed | Chong Kun Dang Pharmaceutical | May 2013 | 24 |
| NCT01692717Healthy Subjects · Brazil | 1 | Completed | Azidus Brasil | May 31, 2013 | 90 |
| NCT01645449Healthy · Germany | 1 | Completed | Dr. Reddy's Laboratories | Aug 2010 | 77 |
| NCT01645423Healthy · India | 1 | Completed | Dr. Reddy's Laboratories | Sep 2009 | 77 |
| NCT01645410Healthy · India | 1 | Completed | Dr. Reddy's Laboratories | Apr 2009 | 71 |
| NCT01645384Healthy · India | 1 | Completed | Dr. Reddy's Laboratories | Jun 2009 | 69 |
| NCT01635946Pharmacokinetics of Isavuconazole · United States | 1 | Completed | Astellas Pharma | Aug 2012 | 24 |
| NCT01499771Healthy · United States | 1 | Completed | Sun Pharmaceutical Industries | Oct 2009 | 80 |
| NCT01499758Healthy · United States | 1 | Completed | Sun Pharmaceutical Industries | Oct 2009 | 80 |
| NCT01495013Diabetes Mellitus, Type 2 · Korea, Republic of, Malaysia, Mexico and more | 3 | Completed | GlaxoSmithKline | Apr 2013 | 427 |
| NCT01370603Hypercholesterolemia | 3 | Completed | Organon | May 2012 | 328 |
| NCT01370590Hypercholesterolemia | 3 | Completed | Organon | Apr 2012 | 406 |
| NCT01218204Dyslipidemias · United States | 2 | Completed | GlaxoSmithKline | Jun 29, 2011 | 287 |
| NCT01299597Sleep Wake Disorders · Germany | 1 | Completed | GlaxoSmithKline | Feb 26, 2010 | 30 |
| NCT01154036Hypercholesterolemia | 3 | Completed | Organon | Sep 2012 | 1,547 |
| NCT01138072Infections · United States | 1 | Completed | GlaxoSmithKline | Aug 2010 | 14 |
| NCT01115985Healthy · Japan | 1 | Completed | Astellas Pharma | Apr 2010 | 24 |
| NCT01029522Dyslipidemias | 4 | Completed | Chong Kun Dang Pharmaceutical | Oct 2008 | 244 |
| NCT00974740Diabetes Mellitus, Type 1 · Germany | 1 | Terminated | Profil Institut für Stoffwechselforschung | Jan 2008 | 63 |
| NCT00917579Hypercholesterolemia · United States | 4 | Completed | Viatris | Sep 2008 | 76 |
| NCT00871351Primary Hypercholesterolemia | 4 | Completed | Organon | May 1, 2010 | 125 |
| NCT00844376Hypercholesterolemia · United States | 4 | Completed | Viatris | Mar 2008 | 12 |
| NCT00827606Hyperlipoproteinemia Type II · United States, Belgium, Canada and more | 3 | Completed | Viatris | Oct 2013 | 272 |
| NCT00782184Hypercholesterolemia | 3 | Completed | Organon | Sep 2010 | 250 |
| NCT00758004Hypercholesterolemia · United States | 1 | Completed | Viatris | Mar 2009 | 76 |
| NCT00754507Hypercholesterolemia · United States | 4 | Completed | Daiichi Sankyo | Jun 2003 | 65 |
| NCT00739999Pediatric Heterozygous Hypercholesterolemia · Canada, Greece, Norway | 1 | Completed | Viatris | May 2009 | 39 |
| NCT00728988Acute Coronary Syndrome · China, Korea, Republic of | 4 | Completed | Viatris | Apr 2010 | 499 |
| NCT00654095Hypercholesterolemia | 3 | Completed | Organon | Jun 1, 2009 | 146 |
| NCT00653796Hypercholesterolemia | 4 | Completed | Organon | Aug 1, 2004 | 148 |
| NCT00650689Hypercholesterolemia | 3 | Completed | Organon | Dec 2004 | 122 |
| NCT00647543Dyslipidemias · Thailand | 4 | Completed | Viatris | 242 |
How it is read
Names in the registry
- “Atorvastatin”, 95 entries
- “atorvastatin”, 36 entries
- “Atorvastatin 20 mg”, 3 entries
- “Comparator: atorvastatin”, 3 entries
- “Atorvastatin 10 mg”, 3 entries
Conditions, from the studies’ own filings
- Hypercholesterolemia, 48 studies
- Dyslipidemias, 15 studies
- Hyperlipidemias, 11 studies
- Diabetes Mellitus, Type 2, 9 studies
- Cardiovascular Diseases, 6 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.